Riparian Pharmaceuticals Inc., a Viva Biotech Holdings Group portfolio company, has entered into an exclusive license agreement and research agreement with Pfizer Inc. in cardiovascular disease.

Recludix Pharma Inc. has entered into a strategic collaboration with Sanofi SA to develop and commercialize first-in-class oral small-molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.

Plasmalogens are a type of phospholipid that play significant roles in membrane fluidity and cellular processes such as vesicular fusion and signal transduction. Previous studies with natural plasmalogens have shown their role in neuroinflammation and memory function improvement.

Newly formed Mage Biologics Inc. is set to receive investment of $28 million from TVM Capital Life Science and Tillotts Pharma AG. Mage plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (MAb) for an initial indication of ulcerative colitis.

Researchers from Wuhan Institute of Biological Products Co. Ltd. and affiliated organizations presented preclinical data for the novel Madin...